Observational Study on the Management of Patients With Non Small Cell Lung Cancer (NSCLC) Adenocarcinoma Tested for the Activating Mutation of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR TK)

AstraZeneca1 site in 1 country2,000 target enrollmentSeptember 2010

ConditionsNon Small Cell Lung Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Non Small Cell Lung Cancer
Sponsor: AstraZeneca
Enrollment: 2000
Locations: 1
Primary Endpoint: The main objective of the study is to determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The main objective of the study is to determine the proportion of patients with M + mutation status among patients with Non Small Cell Lung Cancer adenocarcinoma.

Detailed Description

MSD

Registry

clinicaltrials.gov

Start Date

September 2010

End Date

September 2012

Last Updated

13 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

AstraZeneca

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patient with lung cancer (Non Small Cell Lung Cancer adenocarcinoma)
•Patient for whom a search for the mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed

Exclusion Criteria

•Assessment of mutational status of EGFR is not done

Outcomes

Primary Outcomes

The main objective of the study is to determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma

Time Frame: At baseline

Secondary Outcomes

Describe the therapeutic management according to the mutational status (EGFR M +, EGFR M- and Mx).(12 months / At each visit)
Describe the therapeutic management of patients with EGFR M +.(12 months / At each visit)
Describe the clinical course of patients EGFR-M +, treated for first-line treatment, and then 2nd line treatment, until 31-AUG-2012(12 months / At each visit)